Back to search

University of British Columbia

Inhibition of the phosphoinositide 3-kinase pathway in multiple myeloma mediated through-activation of SHIP

Abstract

dc:description

Multiple myeloma (MM) is a B-lymphocyte neoplasia that remains incurable due in part to intrinsic and acquired drug resistance, despite the numerous conventional therapies available. The growth, survival and anti-apoptosis signals resulting from adhesion and cytokine-mediated interactions between the malignant clones and the bone marrow microenvironment are transduced chiefly through the elevated phosphoinositide 3-kinase (PI3K) signaling pathway, which has been demonstrated essential for disease progression. Many biologically-based therapeutics are in development for MM, but the therapies aimed at abrogating this cascade have shown modest success and often have problems with toxicity. A novel alternate approach in controlling this signaling is activation of an endogenous negative regulator, the inositol phosphatase SHIP. A benefit of targeting SHIP is its restricted expression to hematopoetic cells, thereby limiting potential toxicity to surrounding tissues. Further, the PI3K pathway is involved in the development of drug resistance, and abrogating the cascade can re-sensitize MM cells to conventional therapeutics. Here we demonstrate activation of SHIP is sufficient to inhibit proliferation and induce apoptosis of MM cells in vitro, while having no significant effects on non-hematopoetic cancer cells or lymphocytes lacking SHIP. We also show that SHIP activators enhance the cytotoxicity of current chemotherapeutic agents and provide preliminary results of efficacy in a murine xenograft model. These results not only provide the basis for the further study of a new therapeutic agent to improve MM patient outcome but also propose a new model for studying signal transduction through activating the endogenous negative regulators of the PI3K pathway.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Experimental Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kennah, Michael

Rights

dc:rights
Statement dc:rights
  • For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use.
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/32476

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Kennah, Michael. Inhibition of the phosphoinositide 3-kinase pathway in multiple myeloma mediated through-activation of SHIP. master's thesis, University of British Columbia, 2007. http://hdl.handle.net/2429/32476